Amid one the most consequential transition periods for the U.S. cannabis industry, Trulieve has emerged as a case study in strategic adaption, becoming the first U.S. cannabis operator listed on the New York Stock Exchange.
This industry milestone was made possible with the federal rescheduling of medical marijuana from a Schedule I to a Scheule III substance, and through a careful corporate restructuring that separated medical operations from adult use. Trulieve serves as a powerful reminder that preparedness and strategic optionality are essential tools for cannabis companies operating on the cusp of change.
Key Insights
- The U.S. Department of Justice and Drug Enforcement Administration (DEA) moved state-licensed medical cannabis from Schedule I to Schedule III
- The DEA held a June 29, 2026, hearing to evaluate broader cannabis rescheduling, including potential changes for adult-use cannabis and a ruling has not yet been issued
- These shifts in federal policy are creating opportunities for cannabis operators to expand and restructure
- Trulieve has strategically adapted to the changing industry and has become the first U.S. cannabis operator listed on the New York Stock Exchange
- Operators can look to Trulieve for inspiration on how to restructure and approach a constantly evolving industry
How Trulieve Restructured
When medical marijuana moved into Schedule III, Trulieve underwent a targeted restructuring and separated, or deconsolidated, operations in markets serving both medical and adult-use customers. Simultaneously, it retained consolidated operations that consisted solely of state-licensed medical marijuana facilities. The company also completed a third-party investment tied to that restructuring.
Trulieve effectively:
- Spun off its adult-use business
- Gave a third-party investor an economic interest
- Converted its retained stake into non-voting shares
- Structured the arrangement so the adult-use business would no longer be treated as controlled and consolidated
At the same time, the company preserved an option to reacquire the adult-use business upon broader federal legalization or future rule changes.
Why the Restructuring Worked
The restructuring aligned the company’s consolidated footprint with medical marijuana, the one piece of the business that is now legal at the federal level. Additionally, it reduced the legal and exchange-level friction associated with continued consolidation of adult-use operations, while preserving a strategic upside rather than forcing a permanent exit from adult-use markets.
It’s important to note that Trulieve’s strategic advantage began long before federal rescheduling. As a dominant, highly efficient operator in Florida, Trulieve built a large footprint in one of the biggest cannabis markets in the country.
Key Takeaways for Cannabis Operators
While Trulieve’s exact operational model and restructuring plan will not suit every cannabis company, operators can use the company as a reference point on how to creatively leverage change for success in the next phase of the cannabis industry.
Operators Can Use Change to Their Advantage
The cannabis industry continues to make progress and regulations continue to evolve. With strategic flexibility, companies can leverage these periods of transition to explore new models of structuring and operating. If a system is not working now, that doesn’t mean it will never work. In today’s cannabis market, strategic adjustments to legal entity design, governance, consolidation treatment, and business-line separation can directly affect exchange eligibility and investor access.
Medical Operators May Have a Clearer Near-term Path
For medical-only companies, the federal rescheduling may present a more direct route to operational and capital market readiness than many in the industry previously assumed. U.S. exchange listing is now possible for qualifying medical operators.
Dual-license Operators Should Scenario Plan Now
If the June 29 hearing leads to broader rescheduling, dual medical or adult-use companies may gain a more straightforward path to uplisting and broader strategic repositioning. If it does not, Trulieve’s model demonstrates that carve-outs, deconsolidation strategies, and other restructuring alternatives may still create a viable pathway. Regardless, operators can proactively plan now to prepare a strategic response to either outcome.
Operating Models Matter
Trulieve’s success was supported by a scaled, efficient medical operating base that gave the company a credible foundation to build around once regulatory conditions shifted. Businesses considering similar moves should assess whether their license structure, compliance maturity, systems and market footprint can support a comparable transition.
The Next Phase of the Industry May Accelerate Consolidation
Restructurings and consolidation may grow more common in the next phase of the cannabis industry, with operators are already preparing for possible uplistings and broader capital markets access. As regulatory distinctions sharpen, operators with clean structures, disciplined governance, and scalable financial reporting may be better positioned for transactions, partnerships or public-market opportunities.
Your Guide Forward
As the cannabis industry moves into a more complex and bifurcated regulatory environment, companies need a practical roadmap to adjust. Cherry Bekaert’s Cannabis Accounting, Tax & Business Advisory Services helps operators evaluate how changing federal treatment may impact their business and long-term growth strategy.
Our experienced professionals are uniquely positioned to provide guidance on structuring decisions, valuation, outsourced accounting options, technology and business advisory, and more. If you have questions about rescheduling impacts your business, or how you can prepare for the future, reach out to an advisor.
